Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dabeinong Biotechnology is a leading Chinese agricultural biotechnology company specializing in the development of genetically modified (GM) crop traits. As a core subsidiary of the Dabeinong Group, the company focuses on providing advanced seed technologies for corn and soybeans, primarily targeting insect resistance and herbicide tolerance. Dabeinong was among the first companies to receive biosafety certificates for GM corn in China, positioning it as a pivotal player in the nation's food security and agricultural modernization efforts. Their technological portfolio includes advanced genetic engineering and genome editing tools like CRISPR to enhance crop yields and sustainability. The company operates extensively within China and has successfully expanded its commercial footprint into major South American agricultural markets, including Argentina and Brazil.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dabeinong Biotechnology.